21.5 C
New York
Wednesday, June 7, 2023

Are Things Looking Up For Neurocrine Biosciences Inc. (NASDAQ: NBIX)?

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Neurocrine Biosciences Inc. (NBIX) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.06, or -0.06%, to $94.81. The Neurocrine Biosciences Inc. has recorded 164,402 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Long-Term Improvements and Psychiatric Stability in Patients With Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder at the Schizophrenia International Research Society 2023 Annual Congress.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


Stocks Info

The company is listed on the NASDAQ and operates within the Drug Manufacturers – Specialty & Generic industry segment. At the end of the last regular session, the stock closed at $94.87 and fluctuated between $95.79 as its day high and $93.88 as its day low. The current market capitalization of Neurocrine Biosciences Inc. is $9.36B. A total of 0.99 million shares were traded on the day, compared to an average of 677.88K shares.

Insider Activity

Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, NBIX has seen 1 BUY and 2 SELL insider trades, representing the acquisition of 7,625 and the disposition of 15,697 shares. Over the last 12 months, there were 27 BUYs and 85 SELLs from insiders. Insiders purchased 235,662 shares during that period but sold 455,970.

In the most recent transaction, Cooke Julie sold 11,397 shares of NBIX for 103.89 per share on May 01. After the transaction, the Chief Human Resources Officer now owns 16,169 company shares. In a previous transaction on May 01, RASTETTER WILLIAM H sold 4,300 shares at 101.43 per share. NBIX shares that Director owns now total 42,785.

Among the insiders who sold shares, Cooke Julie disposed of 100 shares on Apr 25 at a per-share price of $103.82. This resulted in the Chief Human Resources Officer holding 27,561 shares of NBIX after the transaction. In another insider transaction, ROBERTS EIRY sold 14,400 shares at $103.48 per share on Apr 24. Company shares held by the Chief Medical Officer now total 26,644.

It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for NBIX in the last 3 months, the mean price target is $124.68 with high estimates of $150.00 and low estimates of $91.00. In terms of 52-week highs and lows, NBIX has a high of $129.29 and a low of $83.33.

As of this writing, NBIX has an earnings estimate of $0.76 per share for the current quarter. EPS was calculated based on a consensus of 18 estimates, with a high estimate of $0.95 per share and a lower estimate of $0.58. The company reported an EPS of $0.88 in the last quarter, which was -23.50% lower than expectations of $1.15.

Balance Sheet Annually/Quarterly

An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. NBIX’s latest balance sheet shows that the firm has $711.30M in Cash & Short Term Investments as of fiscal 2021. There were $440.40M in debt and $245.80M in liabilities at the time. Its Book Value Per Share was $17.35, while its Total Shareholder’s Equity was $1.37B.

Analysts Opinion

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NBIX is Buy with a score of 4.52.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles